← Leaderboards
Robert M. Grant
J. David Gladstone Institutes
$57,229,912
Attributed
$57,229,912
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $17.5M · FY2005–19$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$57,229,912 · 11
By mechanism
U01$41,279,316 · 1
R01$12,281,127 · 3
P01$3,374,501 · 2
P51$292,694 · 4
M01$2,274 · 1
Top collaborators
No co-investigators on record.
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- Douglas F Nixon$54,453,314
Others in their field
Top investigators on “Drug Resistance”
- Judith S. Currier · University Of California Los Angeles$207,752,958
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,910,108
- Ralph Parchment · Leidos Biomedical Research, Inc.$140,676,376
- Daniel R Kuritzkes · Brigham And Women'S Hospital$114,882,802
- Peter C Adamson · National Childhood Cancer Foundation$114,476,581
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,453,088
Research focus
Drug ResistanceHiv-1ViralInfectionUrsidae FamilyHiv InfectionsPersonsCd4 Positive T LymphocytesAntiviral AgentsImmune ResponseExposure ToBaseAfricaPlasmaChemoprophylaxisImmuneViral Load ResultParticipantOralPlacebosCell CountEnrollmentReportingWoman
Grant awards (40)
Chemoprophylaxis and HIV Host Interactions$556,795
R01 · FY2019 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$550,177
R01 · FY2018 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$324,487
R01 · FY2017 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$237,472
R01 · FY2017 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$615,430
R01 · FY2016 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$665,091
R01 · FY2015 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$4,388,511
U01 · FY2011 · AI · contact PI
Chemoprophylaxis and HIV-Host Interactions$876,529
R01 · FY2011 · AI · contact PI
HIV Superinfection after Acute and Recent Infection$646,263
P01 · FY2011 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$15,906,431
U01 · FY2010 · AI · contact PI
Chemoprophylaxis and HIV-Host Interactions$833,172
R01 · FY2010 · AI · contact PI
HIV Superinfection after Acute and Recent Infection$723,040
P01 · FY2010 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$7,860,058
U01 · FY2009 · AI · contact PI
Chemoprophylaxis and HIV-Host Interactions$902,092
R01 · FY2009 · AI · contact PI
HIV Superinfection after Acute and Recent Infection$578,708
P01 · FY2009 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$427,526
U01 · FY2009 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$5,141,967
U01 · FY2008 · AI · contact PI
Chemoprophylaxis and HIV-Host Interactions$749,320
R01 · FY2008 · AI · contact PI
HIV Superinfection after Acute and Recent Infection$534,316
P01 · FY2008 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$2,680,398
U01 · FY2007 · AI · contact PI
Chemoprophylaxis and HIV-Host Interactions$806,636
R01 · FY2007 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men Supplement$716,590
U01 · FY2007 · AI · contact PI
Mechanisms Blocking HIV-1 Superinfection$615,990
R01 · FY2007 · AI · contact PI
HIV Superinfection after Acute and Recent Infection$480,326
P01 · FY2007 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$2,986,662
U01 · FY2006 · AI · contact PI
Mechanisms Blocking HIV-1 Superinfection$851,948
R01 · FY2006 · AI · contact PI
Chemoprophylaxis and HIV Host Interactions$787,145
R01 · FY2006 · AI · contact PI
Chemoprophylaxis for HIV Prevention in Men$1,171,173
U01 · FY2005 · AI
Mechanisms Blocking HIV-1 Superinfection$868,150
R01 · FY2005 · AI
Chemoprophylaxis and HIV Host Interactions$802,225
R01 · FY2005 · AI
GALT SUBSTUDY$2,274
M01 · FY2005 · RR
Mechanisms Blocking HIV-1 Superinfection$787,256
R01 · FY2004 · AI
Chemoprophylaxis and HIV Host Interactions$451,212
R01 · FY2004 · AI
CHARACTERIZATION OF CO-RECEPTOR DEPENDENCE OF SIVSMM$30,974
P51 · FY2004 · RR
MACAQUE SIVMAC239 PROCDUCES LOW LEVEL VIREMIA &STRONG ANTI-VIRAL CTL RESPONSES$87,240
P51 · FY2003 · RR
CHARACTERICATION OF CO-RECEPTOR DEPENDENCE OF PRIMATE ISOLATES OF SIVSMM$87,240
P51 · FY2003 · RR
RAPID VIRAL TURNOVER IN TENOFOVIR TREATED SIV INFECTED SOOTY MANAGBEYS$87,240
P51 · FY2003 · RR
HIV EVOLUTION IN WOMEN$205,924
P01 · FY2002 · HD
HIV EVOLUTION IN WOMEN$205,924
P01 · FY2002 · HD
HIV EVOLUTION IN WOMEN$0
P01 · FY2001 · HD